Don't want ads? Subscribe or login now.

AstraZeneca Unit Ducks Patent Fraud, Not Sham Suit Claims

By Bryan Koenig · December 19, 2025, 6:48 PM EST

A Massachusetts federal judge spared AstraZeneca unit Alexion on Friday from half of a nonprofit insurer's proposed class action, finding the plaintiff too far removed from anticompetitive patent fraud that allegedly...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

EmblemHealth, Inc. v. Alexion Pharmaceuticals, Inc. et al

Case Number

1:25-cv-10985

Court

Massachusetts

Nature of Suit

Anti-Trust

Date Filed

April 16, 2025

Recent Articles By Bryan

January 10, 2025
Infosys Files Antitrust Counterclaims In Trade Secrets Suit
October 15, 2024
'Extraordinary' Blue Cross Deal Includes $2.8B Payout
March 08, 2024
Deadline Drama Briefly Threatens Suit Against Insurer VSP
February 22, 2024
Total Vision's Antitrust Suit Against VSP Kept Largely Intact
December 21, 2023
FTC, DOJ End 2023 With New Guidance, Lingering Challenges
March 20, 2023
DOJ Quietly Abandons UnitedHealth Merger Appeal
February 15, 2023
BCBS Members Want To Duck, Pare BB&B Antitrust Suit
December 20, 2022
State Regulators Want 11th Circ. To Tweak $2.67B BCBS Deal
December 13, 2022
$2.7B BCBS Deal 'Sold Out' Some Claimants, 11th Circ. Told
November 23, 2022
4 Firms, 2 Years, 1 Suit And, Finally, A Done UnitedHealth Deal